NCT01608490终止不适用
Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 315
- 试验地点
- 56
- 主要终点
- Meters: 6 Minute Walk Test - Change From Baseline to 12 Months Follow up
研究概览
简要总结
Multicenter, randomized, assessor-blinded controlled study of safety and effectiveness of the PneumRx, Inc. RePneu Lung Volume Reduction Coil (RePneu LVRC) System
详细描述
This will be a prospective, multicenter, randomized, assessor-blinded, controlled study comparing outcomes between the LVRC and Control Groups. Subjects will be block randomized in an LVRC (Treatment) to Control ratio of 1:1. The randomization will be stratified by homogeneous versus heterogeneous emphysema, to support a balance of patients with differing heterogeneity in both the LVRC and Control Groups.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is greater than or equal to 35 yrs of age
- •CT Scan indicates bilateral emphysema, as determined by the Core Radiology Lab using the criteria presented in the "CT Scoring Plan for Core Radiology Lab"
- •Subject has post-bronchodilator FEV1 less than or equal to 45% predicted
- •Subject has Total Lung Capacity >100% predicted
- •Subject has residual volume (RV) greater than or equal to 175% predicted
- •Subject has marked dyspnea greater than or equal to 2 on mMRC scale of 0-4
- •Subject has stopped smoking for at least 8 weeks prior to entering the study as confirmed by a Cotinine test or other appropriate diagnostic test.
- •Subject has completed a pulmonary rehabilitation program within 6 mos prior to treatment and/or is regularly performing maintenance respiratory rehabilitation if initial supervised therapy occurred more than 6 mos prior to baseline testing.
- •Subject has received Pneumococcal and Influenza vaccinations consistent with local recommendations and/or policy.
- •Subject (and legal guardian, if applicable) has read, understood, and signed the Informed Consent form.
排除标准
- •Subject has severe homogeneous emphysema determined by Core Radiology Lab.
- •Subject has co-morbidities that may significantly reduce subject's ability to improve exercise capacity (e.g., severe arthritis, planned knee surgery) or baseline limitation on 6MWT is not due to dyspnea.
- •Subject has a change in FEV1 of greater than 20% (or, for subjects with pre-bronchodilator FEV1 below 1L, a change of greater than 200mL) post-bronchodilator unless investigator can confirm by other means that subject does not have asthma.
- •Subject has DLCO of less than 20% of predicted.
- •Subject has severe gas exchange abnormalities, PaCO2 of greater than 55mm Hg; PaO2 of less than 45 mm Hg on room air (high altitude criterion: PaO2 of less than 30mm Hg).
- •Subject has a history of recurrent clinically significant respiratory infections, defined as 3 hospitalizations for respiratory infection during the year prior to enrollment.
- •Subject as severe pulmonary hypertension defined by right ventricular systolic pressure of greater than 50mm Hg via right heart catheterization and/or echocardiogram
- •Subject has an inability to walk >140m (150 yd) in 6 minutes
- •Subject has evidence of other severe disease (such as but not limited to lung cancer or renal failure), which in the judgment of the investigator may compromise survival of the subject for the duration of the study.
- •Subject is pregnant or lactating, or plans to become pregnant within the study timeframe.
- •Subject has an inability to tolerate bronchoscopy under moderate sedation or general anesthesia.
- •Subject has clinically significant bronchiectasis.
- •Subject has giant bullae >1/3 lung volume
- •Subject has had previous LVR surgery, lung transplantation, lobectomy or LVR devices or other device to treat COPD in either lung.
- •Subject has been involved in pulmonary drug or device studies within 30 days prior to this study.
- •Subject is taking >20mg prednisone (or equivalent dose of a similar steroid) daily.
- •Subject requires high level chronic immunomodulatory therapy to treat a moderate to severe chronic inflammatory autoimmune disorder.
- •Subject is on an antiplatelet agent (such as Plavix) or anticoagulant therapy (such as Heparin or Coumadin) which cannot be stopped for 7 days prior to the procedure.
- •Subject has any other disease, condition(s) or habit(s) that would interfere with completion of study and follow up assessments, would increase risks of bronchoscopy or assessments, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes.
- •Subject has a sensitivity or allergy to nitinol (nickel-titanium) or its constituent metals.
- •Subject has a known sensitivity to drugs required to perform bronchoscopy.
- •Subject has been diagnosed with alpha-1 antitrypsin deficiency (AATD).
结局指标
主要结局
Meters: 6 Minute Walk Test - Change From Baseline to 12 Months Follow up
时间窗: baseline through 12 months follow up
mean absolute change from baseline at 12 months in the 6 Minute Walk Test comparing test and control groups (median if skewed)
次要结局
- Mean Percent Change in FEV1 From Baseline to 12 Months(BL to 12 months)
- St. George's Respiratory Questionnaire (SGRQ) Mean Absolute Change From Baseline to 12 Months(BL to 12 months)
- 6MWT Responder Analysis(12 months)
研究者
研究点 (56)
Loading locations...
相似试验
已完成
不适用
Evaluation of the PneumRx Lung Volume Reduction Coil to Treat EmphysemaEmphysemaNCT01220908Boston Scientific Corporation36
终止
不适用
Endoscopic Lung Volume Reduction Coil Treatment in Patients With Chronic Hypercapnic Respiratory FailureEmphysemaNCT02996149Universitätsklinikum Hamburg-Eppendorf1
已完成
不适用
Study of PneumRx Endobronchial Coil System in Treatment of Subjects With Severe EmphysemaEmphysemaNCT03360396Boston Scientific Corporation120
已完成
2 期
Evaluation of Physiologic Parameters to Study the Mechanism of Action of the Lung Volume Reduction Coil in Subjects With Homogeneous EmphysemaEmphysemaNCT01421082Boston Scientific Corporation10
已完成
1 期
Randomized Comparison of the RePneu Lung Volume Reduction Coil (LVRC) to Standard of Care for the Treatment of Emphysema (RESET Study)EmphysemaNCT01334307Boston Scientific Corporation47